Why Is Pacira BioSciences Stock Surging Today? Viatris Agrees to $1.65 Billion Acquisition
Pacira BioSciences (NASDAQ: PCRX) stock is surging today after Viatris agreed to acquire the pharmaceutical company for $1.65 billion in cash, giving Pacira shareholders a major premium to the stock's previous market price.
Under the definitive agreement announced on October 8, 2026, Viatris will pay $36.50 per Pacira share in cash. That represents a premium of about 44.8% to Pacira's previous closing price of $25.20. The transaction is expected to close by the end of 2026, subject to shareholder and regulatory conditions.
That acquisition announcement is the main reason Pacira BioSciences stock is moving sharply higher today. The move is not primarily being driven by a new clinical-trial result or quarterly earnings report; it is a takeover repricing.
Why is Pacira stock surging today?
The simplest explanation is that Viatris has put a firm cash value on Pacira.
Before the announcement, PCRX shares closed at $25.20. Viatris' $36.50-per-share offer immediately established a substantially higher reference value for the company. In an acquisition for cash, investors generally move the target company's stock toward the proposed takeover price, although the shares can trade below it because the transaction still has to close.
The deal therefore changes the way investors value Pacira.
Instead of valuing PCRX mainly on its future earnings, pipeline and commercial performance as an independent pharmaceutical company, the market can now evaluate the stock against a specific takeover price and the probability that the transaction will be completed.
That is why a takeover announcement can produce a much larger one-day move than an ordinary corporate update.
What exactly is Viatris buying?
Viatris is acquiring Pacira's portfolio of non-opioid pain treatments, including its two key commercial products, EXPAREL and ZILRETTA.
EXPAREL is a long-acting local analgesic used for postsurgical pain management, while ZILRETTA is an extended-release injection used for osteoarthritis knee pain.
The acquisition gives Viatris access to Pacira's commercial operations, market-access capabilities and research and development infrastructure. Viatris said the transaction fits its strategy of expanding its innovative medicines business and strengthening its position in non-opioid pain management.
For Pacira, the deal provides shareholders with a clear cash exit at $36.50 per share.
Why does Viatris want Pacira?
The acquisition is also important for understanding why Viatris is willing to pay a sizeable premium.
Viatris has been shifting its portfolio toward innovative and patent-protected medicines. Pacira gives the company established commercial products rather than an asset that still needs to pass through years of clinical development and regulatory testing.
Pacira generated approximately $746 million in revenue and $177 million in adjusted EBITDA during the 12 months ended June 30, 2026, according to transaction details reported after the announcement. Viatris expects the acquisition to be immediately accretive to its financial guidance metrics.
That makes the transaction more than a simple pipeline bet.
Viatris is buying an existing commercial business with products already generating revenue, while also gaining opportunities to expand their reach through its larger global infrastructure.
EXPAREL is at the center of the deal
EXPAREL is particularly important because it represents Pacira's largest commercial franchise.
Pacira's second-quarter 2026 results showed total revenue of $192.4 million, up 6% year over year. The company maintained full-year EXPAREL net product-sales guidance of $600 million to $620 million and reported $251 million of cash, cash equivalents and available-for-sale investments at the end of the quarter.
The company has also been working to expand EXPAREL's commercial reach.
In July, UnitedHealthcare began providing separate reimbursement for EXPAREL across eligible outpatient settings. Pacira said the change potentially expands access to its non-opioid postsurgical pain treatment among UnitedHealthcare members.
Just days before the Viatris announcement, Pacira also signed an exclusive agreement with Molteni Farmaceutici to commercialize EXPAREL in the European Union and United Kingdom.
These developments help explain why Pacira has become strategically interesting to a larger pharmaceutical company.
Pacira has been reshaping its business
The Viatris deal comes after Pacira made several strategic changes during 2026.
One notable move was the divestiture of its iovera° business to Zimmer Biomet. Under that transaction, Pacira was entitled to receive up to $140 million, including a $70 million upfront payment and potential future revenue-based milestone payments of up to another $70 million through 2031. The transaction closed on July 31, 2026.
Pacira has described these moves as part of its broader "5x30" strategy and its transition toward an innovation-focused biopharmaceutical company.
It is now effectively becoming part of a much larger pharmaceutical platform if the Viatris acquisition closes.
What happens to PCRX shareholders now?
The key figure for Pacira shareholders is $36.50 in cash per share.
Viatris plans to begin a tender offer for Pacira's outstanding common shares. After the tender offer, Viatris intends to complete a second-step merger for the same consideration.
Pacira's board has unanimously approved the transaction and recommends that shareholders tender their shares. The deal remains subject to customary closing conditions, including the tender of a majority of Pacira's outstanding shares and the expiration of the applicable regulatory waiting period.
If completed, Pacira will become a wholly owned subsidiary of Viatris and its common stock will no longer be listed on Nasdaq.
This means PCRX investors should now focus less on traditional standalone stock catalysts and more on the acquisition process.
Why the stock may trade below $36.50
An important point for investors is that the $36.50 offer price does not necessarily mean PCRX shares will immediately trade at exactly $36.50.
There is a difference between the deal price and the current market price of the target.
The market can keep a discount between the two because the transaction still needs to satisfy its closing conditions. That discount is sometimes called a merger-arbitrage spread.
If the transaction moves smoothly toward completion, the stock can potentially remain close to the offer price. If regulatory problems, shareholder issues or other unexpected obstacles emerge, the spread could widen.
Investors should therefore avoid interpreting the $36.50 offer as an automatic guaranteed market price before closing.
What investors should watch next
For PCRX shareholders, the most important developments are now straightforward.
First, the tender offer. Investors should watch when Viatris formally launches the offer and how shareholders respond.
Second, regulatory clearance. The transaction remains subject to applicable regulatory requirements.
Third, the closing timeline. The companies currently expect the acquisition to close by the end of 2026, assuming the required conditions are satisfied.
Fourth, Viatris' integration plans. The long-term strategic value of the deal will depend on whether Viatris can expand EXPAREL and ZILRETTA while extracting commercial and operational benefits from Pacira.
The bottom line
Pacira BioSciences stock is surging today because Viatris has agreed to acquire the company for $36.50 per share in cash, valuing Pacira's equity at approximately $1.65 billion. The offer represents a roughly 44.8% premium to Pacira's previous closing price and gives shareholders a defined takeover value.
For investors, the story has now shifted from whether Pacira can independently execute its growth strategy to whether the Viatris transaction closes on the announced terms. The key things to watch are the tender offer, regulatory process and expected year-end closing.
Follow the blog for more stock-market, healthcare and business updates.
This article is for informational and educational purposes only and should not be considered investment advice.